Acute Leukemia – Relapsed/Refractory

Genetic mutation/ target

CD33

Wild-Type TP53

IRB# 15601
Phase 1
IMGN779
Intravenously

IRB# 16338:
Phase 1/1b
ALRN-6924
alone, in
combination
with Ara-C

IRB# 7195:
Phase 2
Kinase
Inhibition,
individualized
targeted
therapies

IRB# 17379:
Phase 1b, study
of PDR001
and/or
MBG453 in
combination
with decitabine

IRB# 17583:
Phase 2 study
of CSF1R
inhibitor JNJ-
40346527

IRB# 15993
HLA-A2.01 and
PRAME

Post-transplant

Studies Coming Soon for no specific mutation/target:
IRB# 15588 (SMMART Trial)
IRB# 19290
IRB# 19339
IRB# 18253

http://www.ohsu.edu/research/rda/so/knight.php

Key

Open for Enrollment
In Development
Enrollment on Hold